Alligator Bioscience AB
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Alligator Bioscience AB
With very little cash left in the bank, Idogen is weighing up its options including a reverse merger or liquidation.
The company announced positive results in the second population of its Phase II study of dazodalibep in patients with Sj
The Swedish biotech is expecting intense discussions with prospective partners for mitazalimab, a couple of years after Janssen returned the rights to the CD40 agonist.
Rather than making smaller investments in a larger number of areas, Orion is putting its research euros into oncology and pain management and pulling its Parkinson’s and Alzheimer’s projects, as well as its rare disease programs.
- Large Molecule
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.